Skip to content
Back to explorer
Printable monograph

Mutant IDH1/2 inhibitor

Vorasidenib

Voranigo · IDH1/2 inhibitor

Mutant IDH1/2 inhibitor · approved 2024 · 4 citations

Up to date· through 2026
Fairly sourced4/9 · 4 signals
  • Not met: 4 citations
  • Not met: 12+ references
  • Not met: Accrued over 10+ years (span: 3y)
  • Met: Beyond single case reports
  • Met: High-impact journal
  • Met: Landmark reference
  • Met: Current through 2026
  • Not met: Real-world FAERS signal

Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.

A brain-penetrant IDH inhibitor whose kidney footprint is a benign creatinine bump, not true AKI.

Mildtargeted-modern
Grade 2 IDH1- or IDH2-mutant astrocytoma or oligodendroglioma in adults and pediatric patients >=12 years following surgery

Kidney summary

Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.

Renal dosing
Caution — no defined threshold
No change for CrCl >40 mL/min; at CrCl ≤40 or on dialysis (not studied) the label directs monitoring for increased adverse reactions and modifying the dose accordingly
The atlas summary, paraphrased — not label text. Verbatim label excerpt. Dosing section.
Hemodialysis
Not removed by hemodialysis
Highly protein-bound, hepatically cleared oral IDH inhibitor unlikely to be meaningfully removed by hemodialysis; no renal dose adjustment above CrCl 40 (modifications are hepatotoxicity-driven), closer adverse-reaction monitoring directed at CrCl ≤40/dialysis, and a benign creatinine rise from blocked tubular secretion should not trigger dose reduction.
The atlas summary. Full prose in the Dialyzability section.
FDA boxed warning
None on the excerpted label
Label: VORANIGO, Jun 2026. FDA label section.
Pseudo-AKI
Documented to raise creatinine by blocking its tubular secretion — an isolated creatinine rise on this agent may be pseudo-AKI, not true injury. Confirm with a cystatin-C-based or measured GFR before holding therapy.
Pseudo-AKI in the injury atlas.
§01

Signature kidney injury

Signature lesion

Direct nephrotoxicity is minimal. No vorasidenib-specific AKI signal has been reported; in the registrational INDIGO phase 3 trial the predominant grade >=3 toxicity was hepatic (ALT elevation in ~9.6%), not renal. A mild, reversible serum-creatinine increase — a transporter-mediated pseudo-AKI — is the expected renal finding. A precise renal-event incidence is not quantified.Source: 37272516

Onset & rechallenge

Time to injurySubacute (~1–6 weeks)

Any transporter-mediated creatinine rise appears early, within the first weeks to first cycles, then plateaus in a dose-related, stable fashion.

Distilled from: “A transporter-mediated creatinine rise, if it occurs, appears early (within the first weeks to first cycles) and plateaus; it is dose-related and stable rather than progressive.”

§02

Renal toxicities, ranked

This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.

  1. Pseudo-AKI#1 · Signaturequalitative — no citable incidence

    The great mimic — a rise in creatinine from blocked tubular secretion (OCT2/MATE), NOT true injury. The GFR is intact; confirm with cystatin C before stopping effective therapy.

  2. Prerenal / Hemodynamic AKISecondaryqualitative — no citable incidence

    Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.

§03

Kidney injury

Mechanism of kidney injury

Vorasidenib has no established intrinsic tubular, glomerular, or vascular nephrotoxic mechanism. Any rise in serum creatinine is best understood as a pseudo-AKI: IDH inhibitors of this class (e.g., ivosidenib) inhibit organic cation transporter 2 (OCT2) and multidrug and toxin extrusion (MATE) proteins on the proximal tubule, blocking tubular secretion of creatinine. This elevates measured serum creatinine and lowers the creatinine-based estimated GFR without a true decline in glomerular filtration. Beyond this, kidney involvement is largely prerenal/hemodynamic and uncommon.

Clinical presentation

Typically asymptomatic. The most likely renal-laboratory finding is a modest, stable rise in serum creatinine without oliguria, electrolyte derangement, proteinuria, hematuria, or active urinary sediment. True AKI, interstitial nephritis, or electrolyte wasting are not characteristic. The dominant on-treatment toxicities are hepatic (transaminase elevation) and neurologic, not renal.

Management

For an isolated creatinine rise without other signs of kidney injury, recognize pseudo-AKI: confirm with a cystatin C-based eGFR or by checking that urinalysis and electrolytes are bland, and avoid unnecessary drug interruption. Manage true AKI, if it arises, by the usual approach — assess volume status, review the medication list, and exclude obstruction and other causes.Lesion-level management framework

Risk factors

  • Concurrent nephrotoxins or other OCT2/MATE-inhibiting drugs
  • Baseline CKD where small creatinine shifts cross dosing thresholds
  • Volume depletion (prerenal physiology)
  • Reliance on creatinine-based eGFR rather than cystatin C for monitoring

Prevention

  • Avoid co-administering other OCT2/MATE-inhibiting drugs or nephrotoxins where possible, and correct volume depletion
Anticancer mechanism· how it treats cancer

Vorasidenib is an oral, blood-brain-barrier-penetrant inhibitor of the neomorphic mutant IDH1 (R132) and IDH2 (R172) enzymes. Mutant IDH converts alpha-ketoglutarate to the oncometabolite D-2-hydroxyglutarate (D-2-HG), which dysregulates DNA and histone demethylation and blocks cellular differentiation. By suppressing D-2-HG production, vorasidenib restores epigenetic regulation and slows growth of IDH-mutant grade 2 gliomas, delaying progression and time to next intervention.

§04

Clinical depth

Renal dose adjustment

No dedicated renal-impairment dose adjustment is established for mild-to-moderate impairment; vorasidenib is hepatically metabolized (CYP1A2/CYP3A) and dose modifications in the label are driven by hepatotoxicity, not renal function. Data at CrCl ≤40 mL/min and on dialysis are lacking; there the label directs monitoring for increased adverse reactions and modifying the dose accordingly. A creatinine-based eGFR fall from blocked tubular secretion should not by itself trigger renal dose reduction.

Dialyzability & ESKD dosing

Not characterized. Vorasidenib is a small molecule but is highly protein-bound and extensively hepatically cleared, so it is unlikely to be meaningfully removed by hemodialysis; no formal dialysis data exist.

Differential diagnosis

Distinguish a benign transporter-mediated creatinine rise (pseudo-AKI: stable creatinine, normal cystatin C-based GFR, bland sediment, no electrolyte wasting) from true intrinsic AKI. Consider prerenal azotemia from volume depletion, concomitant nephrotoxins, contrast or other glioma-directed therapies, and — given frequent corticosteroid and anticonvulsant co-medication in glioma patients — drug-related interstitial nephritis from those agents rather than from vorasidenib itself.

Monitoring

  • Serum creatinine / eGFR at baseline and periodically, interpreted with awareness of possible transporter-mediated elevation
  • Hepatic panel (ALT/AST/bilirubin) per label — the principal toxicity to monitor
  • Cystatin C-based GFR when a creatinine rise needs clarification

Key trials & series

  • INDIGO (NCT04164901): phase 3 randomized, double-blind, placebo-controlled trial of vorasidenib 40 mg once daily in residual/recurrent grade 2 IDH-mutant glioma; improved imaging-based PFS and time to next intervention; predominant grade >=3 toxicity was ALT elevation, with no notable renal safety signal

Clinical pearls

  • An isolated creatinine bump on an IDH inhibitor is most likely pseudo-AKI from blocked OCT2/MATE tubular secretion, mirroring ivosidenib; confirm with cystatin C before acting.
  • No vorasidenib-specific AKI, interstitial nephritis, or electrolyte-wasting reports exist; renal claims here are reasoned from class behavior and registrational safety data.
  • In glioma patients, concurrent corticosteroids and antiepileptics are more probable culprits for renal lab changes than vorasidenib itself.
Where it strikes· nephron segments & injury signatures

Nephron segments

Proximal Tubule

Bulk reabsorption + drug uptake (OCT2, OATs)

Beyond the kidney — non-renal toxicities· 2 organ systems

Class-level context for the major non-renal toxicities of the Mutant IDH1/2 inhibitor class.

Pulmonary

Pneumonitis, ILD, effusions, hypertension

  • Differentiation syndrome

Cardiac

Cardiomyopathy, QT, ischemia, myocarditis

  • QT prolongation
§05

References

4 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.

Evidence accrual

4 references · 2023–2026 · 3 since 2024
102023: 1 citation2024: 1 citation2025: 1 citation2026: 1 citation20232026

Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.

  1. 1.LandmarkVorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.Mellinghoff IK, van den Bent MJ, Blumenthal DT, et al. · N Engl J Med · 2023 · PMID 37272516Pivotal INDIGO phase 3 registrational trial establishing efficacy and the safety profile (hepatic ALT elevation as the dominant grade >=3 toxicity; no notable renal signal), supporting the minimal-direct-nephrotoxicity assessment.
  2. 2.Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial.Cloughesy TF, van den Bent MJ, Touat M, et al. · Lancet Oncol · 2025 · PMID 41175888Secondary and exploratory endpoint analysis of INDIGO, providing additional double-blind efficacy, quality-of-life, and tolerability data on vorasidenib.
  3. 3.The Role of Mutant IDH Inhibitors in the Treatment of Glioma.Nakhate V, Lasica AB, Wen PY. · Curr Neurol Neurosci Rep · 2024 · PMID 39302605Review of mutant IDH inhibitors and practical implications of the INDIGO trial, contextualizing vorasidenib's class effects and tolerability among IDH inhibitors.
  4. 4.Current and emerging therapies in IDH-mutant glioma.Nakhate V, Youssef G, Wen PY. · Neurotherapeutics · 2026 · PMID 42085879Up-to-date review situating vorasidenib as the first targeted therapy for IDH-mutant glioma and summarizing its toxicity profile, supporting the conservative renal assessment.
FDA label — boxed warning & renal dosing· renal impairment

Quoted verbatim from this agent's current FDA label (Jun 2026) — not paraphrased or interpreted. Full label on DailyMed .

Renal impairment — from the label

No dosage adjustment is recommended for patients with creatinine clearance (CL cr ) >40 mL/min. The pharmacokinetics and safety of vorasidenib in patients with CL cr ≤40 mL/min or renal impairment requiring dialysis have not been studied [see Clinical Pharmacology (12.3) ] . For patients with CL cr ≤40 mL/min or who require dialysis, monitor for increased adverse reactions and modify the dosage for adverse reactions as recommended [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] .

Kidney rows of the label's dosage tables

From the VORANIGO label (Jun 2026) · DailyMed

No row of this label's 2 dosage tables names a kidney term together with a withhold, reduce, resume or discontinue instruction. That covers those four instructions in the tables only: a table can still set a starting dose by creatinine clearance, and the prose can give other kidney instructions. The full label on DailyMed has both.

What gets reported — FAERS

Everything below is FAERS — adverse events someone chose to report, about 612 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.

  • Reporting odds ratio (ROR) — is kidney injury named in this agent's reports more often than in every other drug's? Above 1 means yes, disproportionately.
  • Renal phenotypes — the same question asked separately for each kind of kidney injury, so the ratios differ from the overall one and from each other.
  • Outcomes — a share of this agent's own reports, not of patients: how many were filed as involving a death or a hospitalization. Not a case-fatality rate.
FAERS reported renal phenotypes· 2 signals

Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.

What reporting says about this profile's documented lesions

  • Pseudo-AKINot queried in FAERS — No MedDRA term set is defined for this phenotype, so FAERS was never asked about it.
  • Prerenal / Hemodynamic AKINot queried in FAERS — No MedDRA term set is defined for this phenotype, so FAERS was never asked about it.
SIADH / Hyponatremia
ROR 2.8895% CI 1.29–6.43· 6 reports· IC025 −0.05 · IC025 does not clear 0
Electrolyte Disturbance
ROR 2.3795% CI 1.34–4.20· 12 reports· IC025 0.22
FAERS outcomes & reporting trend· 2% of reports w/ death · 22.1% w/ hospitalization
2%

Reported with a death outcome

12 of 612 reports

22.1%

Reported with hospitalization

135 of 612 reports

Reports per year

  • 2015: 0 reports
  • 2016: 0 reports
  • 2017: 0 reports
  • 2018: 0 reports
  • 2019: 0 reports
  • 2020: 0 reports
  • 2021: 0 reports
  • 2022: 0 reports
  • 2023: 2 reports
  • 2024: 42 reports
  • 2025: 313 reports
  • 2026: 255 reports

Reports received per year, 2015–2026 · most recent year is partial.

FAERS adverse-event signal — all organ systems· 6 systems · 612 reports

Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.

Disproportionality (acute kidney injury):ROR 0.1795% CI 0.02–1.23· 1 AKI reports· IC025 −5.85·no disproportionate AKI reporting signal (CI spans 1).
Hepatobiliary
Alanine Aminotransferase Increased83Aspartate Aminotransferase Increased68Hepatic Cytolysis34Hepatic Enzyme Increased34Gamma-Glutamyltransferase Increased28
General / constitutional
Fatigue67Fall14Asthenia12Brain Oedema11
Nervous system
Seizure41Headache39Dizziness13Somnolence11
Gastrointestinal
Nausea38Diarrhoea18Vomiting16
Immune / infection
Pneumonia15
Metabolic & electrolyte
Decreased Appetite14
Guidelines & consensus· 13

Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.

General onco-nephrology references

ADQIThe nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupNat Rev Nephrol 2026 · PMID 41361704Provides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.SIRMSIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Radiol Med 2022 · PMID 35303246Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.KDIGOKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerKidney Int 2020 · PMID 33126977Identifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.KDIGOKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationKidney Int 2020 · PMID 33276867Addresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.ADDIKDIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceEClinicalMedicine 2025 · PMID 40290844Provides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.ADDIKDAligning kidney function assessment in patients with cancer to global practices in internal medicineEClinicalMedicine 2025 · PMID 40290845Three consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.ADDIKDA methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEClinicalMedicine 2025 · PMID 40290846Establishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.KDIGODiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Crit Care 2013 · PMID 23394211Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknownsKidney Int 2024 · PMID 38519239Evaluate and risk-stratify CKD, manage to delay progression and its complications, and practise explicit medication management and drug stewardship — the framework the atlas's G1–G5 eGFR banding and every renal dose-adjustment recommendation sit inside. Because the guideline excludes dialysis and transplant recipients by its own statement of scope, its recommendations do not carry to those settings, where this atlas's dialyzability and post-transplant guidance rests on other sources.KDIGOExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney Int 2021 · PMID 34556300Provides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisKidney Int 2024 · PMID 38388147Updates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisKidney Int 2024 · PMID 38182299Updates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.KDIGOExecutive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Kidney Int 2025 · PMID 40975525Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.

Where Vorasidenib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.

Position is a 2-D projection (MDS) of each agent's injury signature, nephron target, severity, and class, so two dots can sit close on the page while differing on an axis the projection flattened — the numbered ranking is computed from the full metric, not from the distance you see. Open the full map.
Phenotype-similar agents· the numbered markers on the map above

Imlunestrant

Inluriyo · Oral selective estrogen-receptor degrader (SERD)

Profile

2025 brain-penetrant oral SERD; renally benign — the only wrinkle is the benign abemaciclib creatinine rise in the combo.

PSEUDOPRE
Mild#1 · 89% phenotype match

Zongertinib

Hernexeos · HER2 TKI

Profile

HER2 exon20 TKI (2025); creatinine rise likely a secretion artifact.

PSEUDOPRE
Mild#2 · 89% phenotype match

Abemaciclib

Verzenio · CDK4/6 inhibitor

Profile

Benign creatinine rise via tubular secretion block.

PSEUDOPRE
Mild#3 · 86% phenotype match

Capmatinib

Tabrecta · MET inhibitor

Profile

Reversible creatinine rise and edema.

PSEUDOPRE
Mild#4 · 86% phenotype match

Tepotinib

Tepmetko · MET inhibitor

Profile

Creatinine rise and peripheral edema.

PSEUDOPRE
Mild#5 · 86% phenotype match

Momelotinib

Ojjaara · JAK/ACVR1 inhibitor

Profile

2023 myelofibrosis JAK inhibitor.

PSEUDOPRE
Mild#6 · 77% phenotype match
Compare Vorasidenib with its nearest agents

Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.